Biotechnology

Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services

* Samsung Biologics, a global leading CDMO, will add mRNA vaccine DS production capability to its existing facility by the first half of 2022 * The addition will enable Samsung Biologics to provide end-to-end mRNA vaccine manufacturing services from bulk drug substance to aseptic fill/finish ...

2021-05-31 19:00 3168
1 ... 161162163164165